Mersana Therapeutics, Inc. executives and directors have only been selling lately: one insider unloaded about $762 of stock over 12 months, with no open-market purchases.
That's worth context: executives sell for plenty of routine reasons, from scheduled trading plans to tax bills. Buying is the rarer, more telling signal.
Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Oct 28, 2025 | Bala Mohan | Executive Officer | Sell | 77 | $9.90 | $762 | SEC |
| Sep 15, 2025 | Huber Martin H. Jr. | CEO | Sell | 2,012 | $7.31 | $15K | SEC |
| Jan 17, 2025 | Mandelia Ashish | Executive Officer | Sell | 3,554 | $0.58 | $2K | SEC |
| Jan 17, 2025 | Protopapas Anna | Director | Sell | 8,637 | $0.58 | $5K | SEC |
| Jan 17, 2025 | Lowinger Timothy B | Executive Officer | Sell | 8,048 | $0.58 | $5K | SEC |
| Jan 17, 2025 | Huber Martin H. Jr. | CEO | Sell | 4,514 | $0.58 | $3K | SEC |
| Jan 17, 2025 | DeSchuytner Brian | CFO | Sell | 8,470 | $0.58 | $5K | SEC |
| Jan 17, 2025 | Carvajal Alejandra | Executive Officer | Sell | 5,096 | $0.58 | $3K | SEC |
| Jan 17, 2025 | Bala Mohan | Executive Officer | Sell | 5,939 | $0.58 | $3K | SEC |
| Jan 16, 2025 | Protopapas Anna | Director | Sell | 6,191 | $0.63 | $4K | SEC |
| Jan 16, 2025 | Mandelia Ashish | Executive Officer | Sell | 1,791 | $0.63 | $1K | SEC |
| Jan 16, 2025 | Lowinger Timothy B | Executive Officer | Sell | 1,794 | $0.63 | $1K | SEC |
| Jan 16, 2025 | DeSchuytner Brian | CFO | Sell | 2,331 | $0.63 | $1K | SEC |
| Jan 16, 2025 | Carvajal Alejandra | Executive Officer | Sell | 952 | $0.63 | $600 | SEC |
| Jan 15, 2025 | Lowinger Timothy B | Executive Officer | Sell | 3,483 | $0.66 | $2K | SEC |
In the last 12 months Mersana Therapeutics, Inc. insiders made open-market purchases worth about $0 and sales worth about $762. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in MRSN was filed on 2025-10-28.
No congressional trades in MRSN were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).